Botanix Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BXPHF research report →
About the company
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis.
- CEO
- Howie McKibbon
- IPO
- 2019
- Employees
- 11
- HQ
- West Perth, WA, AU
Price Chart
- Market Cap
- $22.71M
- P/E
- -0.47
- P/S
- 1.91
- P/B
- 0.76
- EV/EBITDA
- -0.50
- Div Yield
- 0.00%
- Gross Margin
- -118.23%
- Op Margin
- -380.62%
- Net Margin
- -404.72%
- ROE
- -131.13%
- ROIC
- -99.26%
- Revenue
- $5.76M · 178.20%
- Net Income
- $-86,396,186 · -522.91%
- EPS
- $-0.05 · -408.70%
- Op Income
- $-86,342,852
- FCF YoY
- -204.80%
- 52W High
- $0.29
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.06
- Beta
- 0.86
- Avg Volume
- 19.54K
Get TickerSpark's AI analysis on BXPHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BXPHF coverage
Recent articles, reports, and earnings notes.
No research on BXPHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BXPHF report →Similar companies
Peers in the same neighborhood.